In der vorliegenden Arbeit wurden ausgehend von HIV-1 basierten Minigenkonstrukten und der proviralen NL4-3 DNA die Einflüsse der PI3K Signalwegmodulation auf das alternative Spleißen der HIV-1 prä-mRNA sowie auf die Virus Replikation untersucht. Mittels RT-PCR Analysen konnte gezeigt werden, dass die PI3K Inhibition im Falle der HIV-1 basierten Minigenkonstrukte in einer erhöhten Abundanz ungespleißter bzw. intronhaltiger mRNAs resultierte, während im Kontext des Virus die Induktion alternativer Tat Transkriptvarianten nachgewiesen werden konnte. Als Folge der Inhibition des PI3K Signalwegs kam es zu einem vermehrten Einschluss der HIV-1 Leader Exone2/2b und 3. Da der Einschluss dieser Exone durch die hnRNP A/B- und F/H-abhängigen Silencer Elemente ESSV und GI2-1 negativ reguliert wird, wurde vermutet, dass die PI3K Inhibition mit der Funktionalität dieser spleißregulatorischen Aktivität interferiert. Unterstützt wurde diese Hypothese durch Replikationsexperimente mit ESSV und GI2-1 Mutanten in Gegenwart und Abwesenheit des PI3K-Inhibitors. Zusätzlich wurde auch der Einfluss des Inhibitors unter Überexpressionsbedingungen von hnRNP H auf das alternative HIV-1 Spleißen analysiert. In dieser Arbeit konnte ebenfalls gezeigt werden, dass die PI3K Inhibition ein verändertes hnRNP H Spleißmuster bedingt sowie die SR-Protein Phosphorylierung und Expression beeinflusst. Des Weiteren war es im Verlauf der vorliegenden Arbeit möglich, eine Interferenz der PI3K Modulation mit der Virus Replikation nachzuweisen. Die Überexpression der aktivierten Akt-Kinase lies hier nur eine sehr geringe Virus Produktion zu während die PI3K Inhibition diese auf ca. die Hälfte reduzierte. Weiterführende Experimente zeigten, dass die Überexpression der aktivierten Akt-Kinase den nuklearen Export Rev-abhängiger HIV-1 mRNAs zu blockieren scheint. Darüber hinaus beeinflusste die PI3K Inhibition neben dem alternativen HIV-1 Spleißen auch die virale Transkription sowie die zelluläre Translation. Zusammen könnten diese Effekte die reduzierte virale Replikation erklären. Der PI3K Signalweg spielt somit eine zentrale Rolle bei dem alternativen HIV-1 Spleißen und der viralen Replikation und bietet so die Möglichkeit der Entwicklung neuer Ansätze einer antiviralen Therapie. / In this thesis outgoing from HIV-1 based minigenes and the proviral NL4-3 DNA the influences of the PI3K signaling modulation on the alternative HIV-1 pre-mRNA splicing and also the viral replication were investigated. By performing RT-PCR analysis it could be shown that in the case of the minigene experiments the PI3K inhibition displayed an increased amount of unspliced or intron containing mRNAs, while the production of alternative Tat variants was demonstrated in the context of the virus. As a result of the PI3K inhibition an increased inclusion of the HIV-1 leader exons2/2b and 3 was observed. Because the inclusion of these exons is negatively regulated by the hnRNP H/F- and hnRNP A/B-dependent silencere elements ESSV and GI2-1, it was suggested that the PI3K inhibition interferes with the functionality of this splicing regulatory activity. Replication experiments either with GI2-1 or ESSV mutants in the presence or absence of the PI3K-Inhibitior supported this hypothesis. In addition, the influence of the inhibitor on the alternative HIV-1 splicing was analyzed under hnRNP H overexpression conditions. Furthermore, it was shown that the hnRNP H splicing pattern as well as the SR-protein phosphorylation and expression were altered as a consequence of the PI3K inhibition. During this thesis an interference of the PI3K modulation with the viral replication was also shown. The overexpression of the activated Akt kinase nearly prevented viral production while the PI3K inhibition reduced viral production by half. In further experiments it was shown that the overexpression of the activated Akt kinase seems to block the nuclear export of Rev-dependent HIV-1 mRNAs. In addition, beside the effect on the viral splicing pattern the PI3K inhibition also showed an influence on the viral transcription and the cellular translation suggesting that the sum of all these effects could contribute to the reduced virus production. These findings demonstrate that the PI3K signaling pathway has indeed a central influence on the alternative HIV-1 splicing as well as on the viral replication and may offer a new approach for antiviral therapy.

Die Interaktion des Masernvirus mit T-Zellen stört die Aktivierung der TCR-Signalkaskade durch die Hemmung der Phosphatidylinositol-3-Kinase (PI3K), die zur Einstellung der T-Zell-Funktionen führt und dadurch nachgeschaltete (downstream) Signalwege sowie den Eintritt in den Zellzyklus, aber auch die Genexpression reguliert. Infolgedessen können die Aktivität spleißregulatorischer Faktoren sowie die Spleißmuster von mRNAs verändert werden, wie zum Beispiel bei der alternativ gespleißten SHIP1-Isoform SIP110, die eine T-Zell-inhibitorische Aktivität zeigt. Um alternativ gespleißte (AS) und differentiell regulierte (RG) Transkripte in T-Zellen infolge von PI3K-Inhibition zu erfassen, wurde ein Human Exon 1.0 ST Array an RNA-Proben von humanen T-Zellen, 24 h stimuliert und stimuliert/ PI3K-inhibiert, durchgeführt. Durch die Anwendung geeigneter bioinformatischer Algorithmen konnten spezifisch in PI3K-inhibierten Zellen angereicherte Transkripte nachgewiesen und in die Kategorien AS (2192 Gene) und RG (619 Gene) eingeteilt werden. Ausgewählte Gene wurde mittels RT-PCR und qPCR validiert, gefolgt von der funktionellen Annotation beider Genlisten. AS Gene konnten verstärkt in ECM-Rezeptor Interaktionen, fokaler Adhäsion, Proliferation, Zytoskelettorganisation und Tumorsignalwegen gefunden werden, während RG Gene eher in der DNA-Replikation, DNA-Reparatur und Stressantwort vertreten waren. Gene beider Gruppen konnten auf Signalwege bezogen werden, die essentiell für den TCR-Signalweg, die Zytoskelettdynamik und den Zellzykluseintritt waren. Das stützt die Annahme, dass die Außerkraftsetzung der PI3K-Schüsselprozesse der T-Zell-Aktivierung sowohl auf der Ebene der RG als auch der AS Gene wirkt. Über die Ingenuity Pathway Analyse konnten wir unsere Genlisten mit Genen vergleichen, die bereits auf solche Schlüsselprozesse und die Viabilität bezogen werden können. In der Überschneidung wurden z.B. die AS GTP-Austauschfaktoren Vav1 und Vav3 gefunden, die für die Übersetzung extrazellulärer Signale in Zytoskelettdynamik, Proteinphosphatasen und Adapter von Bedeutung sind. Ausgewählte Gene (AS - FBXO6 und LAT2, RG - SLFN5) wurden aus PI3K-arretierten T-Zellen kloniert und deren Effekt auf grundlegende zelluläre Funktionen durch Überexpression in HEK293T-Zellen überprüft. Die Fusionsproteine veränderten weder die Zellviabilität noch die Proliferation dieser Zellen. Über einen auf siRNA basierenden Knockdown wurde überprüft, ob das RG Gene SLFN5 als Suppressor auf die T-Zell-Aktivierung agiert. Der Knockdown in primären T-Zellen zeigte keinen Einfluss auf die Zellviabilität, Proliferation und Polarisation. Jedoch konnte ein signifikanter Effekt auf die T-Zell-Adhärenz auf Fibronektin gezeigt werden, was darauf schließen lässt, dass SLFN5 die T-Zell-Adhärenz negativ reguliert. Des Weiteren wurde die MV-induzierte Regulation selektierter Gene betrachtet und Unterschiede in der Regulation im Vergleich zur direkten PI3K-Inhibition festgestellt. Ein Grund dafür könnte sein, dass das MV eine Inhibition auf vielen Ebenen induziert, anstelle der alleinigen PI3K-Inhibition. Abschließend wurde untersucht, ob ausgewählte Gene an der Regulation in verschiedenen T-Zelllinien beteiligt sind und als Tumorsuppressoren agieren könnten. FBXO6 als Regulator der CHK1-Stabilität wurde in den meisten Zelllinien nicht exprimiert. Die Annahme, dass eine Stress-induzierte defekte Ubiquitinierungsmaschinerie an der Resistenz von Tumorzellen auf Chemotherapeutika beteiligt ist, macht FBXO6 zu einem interessanten Kandidaten als Biomarker für Tumorsensitivität gegenüber Krebsmedikamenten. Diese Annahme bedarf jedoch weiterer Untersuchungen. / The interaction of measles virus (MV) with T cells interferes with the activation of the TCR-signaling by the inhibition of the phosphatidylinositol-3-kinase (PI3K), leading to the termination of T cell functions and consequently to the regulation of downstream signaling as well as cell cycle entry. PI3K-inhibition also affects the activity of splice regulatory elements and the splicing pattern of mRNAs, as for example the alternatively spliced SHIP1 isoform SIP110 that shows T cell inhibitory activity. To integrate early alternatively spliced (AS) and differentially regulated (RG) transcripts in response to PI3K interference in T cells at a general level, we performed a Human Exon 1.0 ST Array analysis on RNAs isolated from human T cells PI3K-inhibited or not prior to 24h stimulation. Applying suitable bioinformatic algorithms, transcripts detected specifically in PI3K-inhibited cells were assigned to categories defining RG (619 genes) and AS species (2192 genes). A selection of genes was validated by RT-PCR and qPCR followed by functional annotation of both gene lists. AS genes were found to be enriched in ECM-receptor interactions, focal adhesion, proliferation, cytoskeleton organization and tumor signaling, while RG genes were rather related to processes as DNA-replication, DNA-repair and stress response. Some genes that belonged to both groups target pathways essential for TCR-signaling, cytoskeletal dynamics and cell cycle entry, strongly support the notion that PI3K abrogation interferes with key T cell activation processes at the level of differential regulation as well as alternative splicing. Using Ingenuity Pathway Analysis we compared our gene lists to genes already known to specifically relate to key T cell functions and viability. In the overlap we found for example AS GTP-exchange factors Vav1 and Vav3 important for translating extracellular signals into cytoskeletal dynamics, protein phosphatases and adaptors. Selected candidate genes (AS - FBXO6 und LAT2, RG - SLFN5) were cloned from PI3K-arrested T cells into the pEGFP-vector and tested by overexpression in HEK293T for their effect on basic cell functions. These fusion proteins did not affect viability and proliferation of these cells. Using siRNA-based knockdown the potential of the RG gene SLFN5 to act as suppressors of key steps in T cell activation was tested. Its knockdown in primary T cells did not affect cell viability, proliferation and polarization. However, T cell adherence on fibronectin was significantly enhanced indicating that SLFN5 negatively regulates T cell adhesion to the ECM. Additionally we had a look at the MV induced regulation of selected genes and found a difference of the regulation in comparison to direct PI3K-inhibition. A reason for these unexpected results could be that MV induces a multi-level inhibition, rather than PI3K-inhibition only. Finally we wanted to find out, if selected genes were also implicated in the regulation of different T cell lines and therefore could act as tumor suppressors. FBXO6, a regulator of CHK1 stability, for example was not expressed in most investigated cell lines. Assuming that a stress-induced defective ubiquitination complex is involved in the resistance of tumor cells to chemotherapeutic agents FBXO6 might be an interesting candidate as biomarker for tumor sensitivity to cancer medication. If some of these differences in regulation are the result of immortalization, corresponding genes could consequently act as tumor suppressor. This issue has to be subject to further research.

Univ., Diss., 2006--Frankfurt (Main) / Enth. Sonderabdr. aus versch. Zeitschr. - Zsfassung in dt. und engl. Sprache

Stuttgart, Univ., Diss., 2005.

Techn. University, Diss., 2004--Dresden.

Messenger RNA (mRNA) is transcribed by RNA polymerase II (Pol II) and has to undergo multiple processing events before it can be translated into a protein: a cap structure is added to its 5’ end, noncoding, intervening sequences (introns) are removed and coding exons are ligated together and a poly(A) tail is added to its 3’end. Splicing, the process of intron removal, is carried out in the spliceosome, a megacomplex comprehending up to 300 proteins. The core components of the spliceosome that directly interact with the pre-mRNA are the small nuclear ribonucleoprotein particles (snRNPs). They consist of one of the U-rich snRNAs U1, U2, U4, U5 or U6 together with several particle-specific proteins and core proteins. All mRNA processing events can occur co-transcriptionally, i.e. while the RNA is still attached to the gene via Pol II. The in vivo studies of co-transcriptional RNA processing events had been possible only in special biological systems by immunoelectron microscopy and only recently, Chromatin Immunoprecipitation (ChIP) made it possible to investigate cotranscriptional splicing factor assembly on genes. My thesis work is divided into two parts: Part I shows that the core components of the splicing machinery are recruited co-transcriptionally to mammalian genes in vivo by ChIP. The co-transcriptional splicing factor recruitment is dependent on active transcription and the presence of introns in genes. Furthermore, a new assay was developed that allows for the first time the direct monitoring of co-transcriptional splicing in human cells. The topoisomerase I inhibitor camptothecin increases splicing factor accumulation on the c-fos gene as well as co-transcriptional splicing levels, which provides direct evidence that co-transcriptional splicing events depend on the kinetics of RNA synthesis. Part II of the thesis is aimed to investigate whether Pol II has a functional role in the biogenesis of the U6 snRNA, which is the RNA part of the U6 snRNP involved in splicing. Pol III had been shown to transcribe the U6 snRNA gene, but ChIP experiments revealed that Pol II is associated with all the active U6 snRNA gene promoters. Pol II inhibition studies uncovered that U6 snRNA expression and probably 3’end formation is dependent on Pol II.

It is currently believed that the splicing of most pre-mRNAs occurs, at least in part, co-transcriptionally. In order to validate this principle in yeast and establish an experimental system for monitoring spliceosome assembly in vivo, I have employed the chromatin immunoprecipitation (ChIP) assay to study co-transcriptional splicing events. Here, I use ChIP to examine key questions with respect to the recent proposal that RNA polymerase II (Pol II) recruits pre-mRNA splicing factors to active genes. In my thesis, I address: 1) whether the U1 snRNP, which binds to the 5¡¦ splice site of each intron, is recruited co-transcriptionally in vivo and 2) if so, where along the length of active genes the U1 snRNP is concentrated. U1 snRNP accumulates on downstream positions of genes containing introns but not within promoter regions or along intronless genes. More specifically, accumulation correlated with the presence and position of the intron, indicating that the intron is necessary for co-transcriptional U1 snRNP recruitment and/or retention (Kotovic et al., 2003). In contrast to capping enzymes, which bind directly to Pol II (Komarnitsky et al., 2000; Schroeder et al., 2000), the U1 snRNP is poorly detected in promoter regions, except in genes harboring promoter-proximal introns. Detection of the U1 snRNP is dependent on RNA synthesis and is abolished by intron removal. Microarray data reveals that intron-containing genes are preferentially selected by ChIP with the U1 snRNP furthermore indicating recruitment specificity to introns. Because U1 snRNP levels decrease on downstream regions of intron-containing genes with long second exons, our lab is expanding the study to 3¡¦ splice site factors in hopes to address co-transcriptional splicing. In my thesis, I also focus on questions pertaining to the requirements for recruitment of the U1 snRNP to sites of transcription. To test the proposal that the cap-binding complex (CBC) promotes U1 snRNP recognition of the 5¡¦ splice site (Colot et al., 1996), I use a ?´CBC mutant strain and determine U1 snRNP accumulation by ChIP. Surprisingly, lack of the CBC has no effect on U1 snRNP recruitment. The U1 snRNP component Prp40p has been identified as playing a pivotal role in not only cross-intron bridging (Abovich and Rosbash, 1997), but also as a link between Pol II transcription and splicing factor recruitment (Morris and Greenleaf, 2000). My data shows that Prp40p recruitment mirrors that of other U1 snRNP proteins, in that it is not detected on promoter regions, suggesting that Prp40p does not constitutively bind the phosphorylated C-terminal domain (CTD) of Pol II as previously proposed. This physical link between Pol II transcription and splicing factor recruitment is further tested in Prp40p mutant strains, in which U1 snRNP is detected at normal levels. Therefore, U1 snRNP recruitment to transcription units is not dependent on Prp40p activity. My data indicates that co-transcriptional U1 snRNP recruitment is not dependent on the CBC or Prp40p and that any effects of these players on spliceosome assembly must be reflected in later spliceosome events. My data contrasts the proposed transcription factory model in which Pol II plays a central role in the recruitment of mRNA processing factors to TUs. According to my data, splicing factor recruitment acts differently than capping enzyme and 3¡¦ end processing factor recruitment; U1 snRNP does not accumulate at promoter regions of intron-containing genes or on intronless genes rather, accumulation is based on the synthesis of the intron. These experiments have lead me to propose a kinetic model with respect to the recruitment of splicing factors to active genes. In this model, U1 snRNP accumulation at the 5¡¦ splice site requires a highly dynamic web of protein-protein and protein-RNA interactions to occur, ultimately leading to the recruitment and/or stabilization of the U1 snRNP.

It is currently believed that the splicing of most pre-mRNAs occurs, at least in part, co-transcriptionally. In order to validate this principle in yeast and establish an experimental system for monitoring spliceosome assembly in vivo, I have employed the chromatin immunoprecipitation (ChIP) assay to study co-transcriptional splicing events. Here, I use ChIP to examine key questions with respect to the recent proposal that RNA polymerase II (Pol II) recruits pre-mRNA splicing factors to active genes. In my thesis, I address: 1) whether the U1 snRNP, which binds to the 5¡¦ splice site of each intron, is recruited co-transcriptionally in vivo and 2) if so, where along the length of active genes the U1 snRNP is concentrated. U1 snRNP accumulates on downstream positions of genes containing introns but not within promoter regions or along intronless genes. More specifically, accumulation correlated with the presence and position of the intron, indicating that the intron is necessary for co-transcriptional U1 snRNP recruitment and/or retention (Kotovic et al., 2003). In contrast to capping enzymes, which bind directly to Pol II (Komarnitsky et al., 2000; Schroeder et al., 2000), the U1 snRNP is poorly detected in promoter regions, except in genes harboring promoter-proximal introns. Detection of the U1 snRNP is dependent on RNA synthesis and is abolished by intron removal. Microarray data reveals that intron-containing genes are preferentially selected by ChIP with the U1 snRNP furthermore indicating recruitment specificity to introns. Because U1 snRNP levels decrease on downstream regions of intron-containing genes with long second exons, our lab is expanding the study to 3¡¦ splice site factors in hopes to address co-transcriptional splicing. In my thesis, I also focus on questions pertaining to the requirements for recruitment of the U1 snRNP to sites of transcription. To test the proposal that the cap-binding complex (CBC) promotes U1 snRNP recognition of the 5¡¦ splice site (Colot et al., 1996), I use a ?´CBC mutant strain and determine U1 snRNP accumulation by ChIP. Surprisingly, lack of the CBC has no effect on U1 snRNP recruitment. The U1 snRNP component Prp40p has been identified as playing a pivotal role in not only cross-intron bridging (Abovich and Rosbash, 1997), but also as a link between Pol II transcription and splicing factor recruitment (Morris and Greenleaf, 2000). My data shows that Prp40p recruitment mirrors that of other U1 snRNP proteins, in that it is not detected on promoter regions, suggesting that Prp40p does not constitutively bind the phosphorylated C-terminal domain (CTD) of Pol II as previously proposed. This physical link between Pol II transcription and splicing factor recruitment is further tested in Prp40p mutant strains, in which U1 snRNP is detected at normal levels. Therefore, U1 snRNP recruitment to transcription units is not dependent on Prp40p activity. My data indicates that co-transcriptional U1 snRNP recruitment is not dependent on the CBC or Prp40p and that any effects of these players on spliceosome assembly must be reflected in later spliceosome events. My data contrasts the proposed transcription factory model in which Pol II plays a central role in the recruitment of mRNA processing factors to TUs. According to my data, splicing factor recruitment acts differently than capping enzyme and 3¡¦ end processing factor recruitment; U1 snRNP does not accumulate at promoter regions of intron-containing genes or on intronless genes rather, accumulation is based on the synthesis of the intron. These experiments have lead me to propose a kinetic model with respect to the recruitment of splicing factors to active genes. In this model, U1 snRNP accumulation at the 5¡¦ splice site requires a highly dynamic web of protein-protein and protein-RNA interactions to occur, ultimately leading to the recruitment and/or stabilization of the U1 snRNP.

Messenger RNA (mRNA) is transcribed by RNA polymerase II (Pol II) and has to undergo multiple processing events before it can be translated into a protein: a cap structure is added to its 5’ end, noncoding, intervening sequences (introns) are removed and coding exons are ligated together and a poly(A) tail is added to its 3’end. Splicing, the process of intron removal, is carried out in the spliceosome, a megacomplex comprehending up to 300 proteins. The core components of the spliceosome that directly interact with the pre-mRNA are the small nuclear ribonucleoprotein particles (snRNPs). They consist of one of the U-rich snRNAs U1, U2, U4, U5 or U6 together with several particle-specific proteins and core proteins. All mRNA processing events can occur co-transcriptionally, i.e. while the RNA is still attached to the gene via Pol II. The in vivo studies of co-transcriptional RNA processing events had been possible only in special biological systems by immunoelectron microscopy and only recently, Chromatin Immunoprecipitation (ChIP) made it possible to investigate cotranscriptional splicing factor assembly on genes. My thesis work is divided into two parts: Part I shows that the core components of the splicing machinery are recruited co-transcriptionally to mammalian genes in vivo by ChIP. The co-transcriptional splicing factor recruitment is dependent on active transcription and the presence of introns in genes. Furthermore, a new assay was developed that allows for the first time the direct monitoring of co-transcriptional splicing in human cells. The topoisomerase I inhibitor camptothecin increases splicing factor accumulation on the c-fos gene as well as co-transcriptional splicing levels, which provides direct evidence that co-transcriptional splicing events depend on the kinetics of RNA synthesis. Part II of the thesis is aimed to investigate whether Pol II has a functional role in the biogenesis of the U6 snRNA, which is the RNA part of the U6 snRNP involved in splicing. Pol III had been shown to transcribe the U6 snRNA gene, but ChIP experiments revealed that Pol II is associated with all the active U6 snRNA gene promoters. Pol II inhibition studies uncovered that U6 snRNA expression and probably 3’end formation is dependent on Pol II.